Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.titanbiotechltd.com | |
Market Cap | 238.33 Cr. | |
Enterprise Value(EV) | 240.94 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 32.49 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 8.88 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 25.92 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 122.85 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.35 | Calculated using Price: 288.40 |
Dividend Yield | 0.52 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.83 Cr. | 8,263,700 Shares |
FaceValue | 10 | |
Company Profile | ||
Titan Biotech was established in 1992 with an objective of serving the scientific community and mankind by way of providing good quality of biological products i.e. protein hydrolysis, peptones and their derivatives, extracts, dehydrated microbiological culture media, plant tissue culture media and laboratory chemicals. |
1 Day |
|
-1.27% |
1 Week |
|
-2.60% |
1 Month |
|
-2.00% |
3 Month |
|
+7.35% |
6 Month |
|
+30.94% |
1 Year |
|
-5.66% |
2 Year |
|
+81.44% |
5 Year |
|
+312.29% |
10 Year |
|
+1822.67% |
8 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 7.97 | 8.42 | 9.80 | 11.27 | 13.84 | 21.97 | 58.74 | 35.32 | |
Return on Capital Employed (%) | 12.21 | 12.06 | 12.32 | 13.59 | 14.88 | 21.45 | 60.80 | 39.42 | |
Return on Assets (%) | 4.87 | 4.81 | 4.73 | 4.85 | 6.32 | 10.89 | 33.50 | 21.71 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 20 | 22 | 23 | 24 | 32 | 39 | 69 | 99 | 102 | |
Non Curr. Liab. | 3 | 5 | 16 | 20 | 15 | 14 | 9 | 13 | 6 | |
Curr. Liab. | 10 | 13 | 12 | 12 | 17 | 22 | 30 | 34 | 17 | |
Minority Int. | 1 | 1 | 1 | 2 | 2 | 4 | 7 | |||
Equity & Liab. | 34 | 40 | 52 | 58 | 66 | 78 | 111 | 152 | 124 | |
Non Curr. Assets | 12 | 16 | 23 | 28 | 30 | 32 | 42 | 52 | 53 | |
Curr. Assets | 21 | 24 | 30 | 30 | 36 | 46 | 69 | 100 | 70 | |
Misc. Exp. not W/O | 0 | 0 | 0 | 0 | 0 | |||||
Total Assets | 34 | 40 | 52 | 58 | 66 | 78 | 111 | 152 | 124 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 40 | 46 | 53 | 57 | 65 | 79 | 142 | 153 | 146 | |
Other Income | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | |
Total Income | 41 | 46 | 53 | 58 | 66 | 80 | 143 | 154 | 148 | |
Total Expenditure | -36 | -42 | -47 | -50 | -56 | -66 | -96 | -112 | -111 | |
PBIDT | 4 | 4 | 6 | 7 | 10 | 14 | 47 | 42 | 36 | |
Interest | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -1 | -1 | |
Depreciation | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -3 | -3 | |
Taxation | -1 | -1 | -1 | -1 | -2 | -3 | -11 | -10 | -8 | |
Exceptional Items | 1 | 0 | ||||||||
PAT | 2 | 2 | 2 | 3 | 4 | 8 | 32 | 29 | 25 | |
Minority Interest | 0 | 0 | -1 | -1 | -3 | -1 | ||||
Share Associate | 0 | 1 | ||||||||
Other Related Items | ||||||||||
Consolidated Net Profit | 2 | 2 | 2 | 3 | 4 | 7 | 30 | 26 | 27 | |
Adjusted EPS | 2 | 2 | 3 | 3 | 4 | 9 | 37 | 31 | 32 |
Particulars | 8 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -2 | 5 | 0 | 2 | 5 | 6 | 19 | 23 | |
Cash Fr. Inv. | -3 | -5 | -8 | -6 | -4 | -2 | -5 | -19 | |
Cash Fr. Finan. | 3 | 2 | 9 | 0 | 0 | -4 | -11 | 6 | |
Net Change | -2 | 2 | 1 | -3 | 1 | 0 | 4 | 10 | |
Cash & Cash Eqvt | 0 | 4 | 4 | 1 | 2 | 2 | 5 | 16 |
Fri, 27 Jan 2023
Board Meeting Intimation for Considering Inter Alia Unaudited Quarterly Financial Results For Quarter Ended 31St December 2022 TITAN BIOTECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2023 inter alia to consider and approve inter alia unaudited quarterly financial results for quarter ended 31st December 2022 |
Tue, 24 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation for loss of shares/issue of duplicate shares to shareholder. |
Sat, 07 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate for quarter ended 31st December 2022 under regulation 74(5) of SEBI (DP) Regulations . |
Fri, 27 Jan 2023 |
|
|
|
|
|